The United Kingdom and the United States have forged a key commercial pact that will preserve no levies on UK drug shipments being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This pledge guarantees that import taxes on these key exports will be held at nothing for a period of 36 months.
This development is in response to earlier warnings to hike tariffs on patented drug imports, with increases floated up to one hundred percent.
"This arrangement between the UK reinforces the international landscape for new treatments and brings long-overdue balance to transatlantic pharmaceutical trade," a release declared.
Commercial Significance
Drugs are one of the Britain's biggest export categories to the United States, which is clearly the primary market for major companies like GSK and AstraZeneca.
Trade data show that in the year to the end of the third quarter, the UK sold medicines totaling over eleven billion pounds to the US. This amount represented 17.4% of British export trade in that timeframe.
"This agreement safeguards jobs, boosts capital expenditure and facilitates the UK to establish itself as a global hub for medical research," a government official remarked.
Specific NHS Changes
The agreement involves several notable changes from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to prevent overspending will be limited at 15%. Last year, refunds were more than 20%.
Industry Background
This agreement comes amid a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were intensified by assertions that US patients were paying several times more for the identical medicines than people in the other developed nations.
In recent months, several large drug company projects in the UK have been delayed or scrapped, while major investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the last ten years.
